Table 1.
Clinical and pathologic characteristics (n = 1457).
Table 2.
Treatment details (n = 1457).
Table 3.
Univariate Cox regression of biochemical progression-free survival.
Table 4.
Multivariate Cox regression of biochemical progression-free survival.
Fig 1.
Kaplan-Meier curves for biochemical progression-free survival of all study patients.
Fig 2.
(A) Kaplan-Meier curves for biochemical progression-free survival of all patients stratified according to pretreatment blood prostate-specific antigen (PSA) levels: ≤ 10 ng/ml vs. > 10 ng.ml. (B) Kaplan-Meier curves for biochemical progression-free survival of patients with Gleason score (GS) ≤ 6 stratified according to pretreatment blood PSA levels: ≤ 10 ng/ml vs. > 10 ng.ml.
Fig 3.
Kaplan-Meier curves for biochemical progression-free survival of all patients stratified according to Gleason score (GS): ≤ 6 vs. 7.
Fig 4.
(A) Kaplan-Meier curves for biochemical progression-free survival of all patients stratified according to D’Amico risk grouping: low vs. intermediate. (B) Kaplan-Meier curves for biochemical progression-free survival of two intermediate risk groups: patient with Gleason score (GS) ≤ 6 and pretreatment blood prostate-specific (PSA) levels > 10 ng.ml vs. patients with GS = 7 and any pretreatment PSA levels.
Fig 5.
Kaplan-Meier curves for biochemical progression-free survival of all patients stratified according to prostate-specific antigen density (PSAD): ≤ 0.15 vs. > 0.15.
Fig 6.
(A) Kaplan-Meier curves for biochemical progression-free survival of all patients stratified according to whether they received (Yes) androgen deprivation therapy (ADT) or did not receive ADT (No). (B) Kaplan-Meier curves for biochemical progression-free survival of patients with Gleason score (GS) ≤ 6 and prostate-specific antigen (PSA) ≤ 10 ng/ml stratified according to whether they received (Yes) ADT or did not receive ADT (No). (C) Kaplan-Meier curves for biochemical progression-free survival of patients with Gleason score (GS) ≤ 6 and PSA > 10 ng/ml stratified according to whether they received (Yes) ADT or did not receive ADT (No).
Fig 7.
Kaplan-Meier curves for biochemical progression-free survival of all patients stratified according to the prostate biopsy percent of positive cores (PPC): ≤ 50 vs. > 50.